MCCQE1 practice questions: cancer screening in Canada, and where the provinces disagree
Three full clinical vignettes with worked explanations. Screening is the topic where Canadian and American answers diverge most sharply — cervical screening starts later here — and it is also the topic where Canada does not agree with itself. A national guideline and a provincial programme can give different advice to the same patient on the same day.
These are free samples. The full platform builds papers from the Canadian guidelines, grades them, and tracks every topic you get wrong.
Why this topic has two right answers
Screening recommendations in Canada come from two places. The Canadian Task Force on Preventive Health Care issued national guidance. Provincial and territorial programmes decide who actually gets invited, from what age, and how often — and they do not all follow the Task Force, or each other.
Read that first verb again. The Task Force's own history page records that its mandate ended on 31 March 2026. Its guidelines remain on its site and are still the national documents most often cited, but nobody is updating them, and several are now marked archived. That is an unusual situation and it is worth stating plainly rather than writing around: Canadian national guidance on cancer screening is, at the moment, a set of standing documents without a standing body behind them.
The gap between guidance and practice is correspondingly wide. The Task Force's breast guidance and the Canadian Cancer Society's position differ on women in their forties. Colorectal screening starts at 50 in most of the country, and at 45 in Ontario and Prince Edward Island. Cervical programmes are mid-migration from cytology to HPV testing, province by province.
For the exam, this is manageable if you hold two things separately: the principle, which is stable and is what most questions test, and the local programme detail, which a well-written question will tell you or will avoid. If a stem names a province, read it as part of the question.
Where things stand, as of November 2026
| Cancer | National guidance | What the programmes do |
|---|---|---|
| Cervical | The Task Force's cervical guidance dates from 2013 and is Pap-based. It recommends against routinely screening under 20 and against routinely screening at 20–24, and screens 25 to 69 every 3 years; above 70, screening may cease if the woman has been adequately screened. It does not address HPV testing at all, and no update was published before the Task Force's mandate ended. | Moving to HPV testing, jurisdiction by jurisdiction. The Canadian Partnership Against Cancer counts six jurisdictions that have partly or fully implemented it: the Northwest Territories, British Columbia, Alberta, Ontario, Prince Edward Island, and Newfoundland and Labrador. Ontario completed its move to HPV primary screening with reflex cytology in March 2025; Prince Edward Island changed in May 2023. Intervals are set programme by programme — British Columbia, for example, screens every 3 years by Pap or 5 years by HPV self-screening. Self-collection is offered in several programmes. |
| Breast | The last published Task Force breast guideline is the 2018 one: it recommends against routine mammography at 40–49 in women not at increased risk, and screening every 2 to 3 years from 50 to 74. A 2024 update was released as draft recommendations. It framed breast screening as a personal choice across 40–74, suggested screening every 2 to 3 years for those who want it, and suggested not screening at 75 and over. It was never finalised — the Task Force's own site now carries it marked archived and headed “THESE ARE DRAFT RECOMMENDATIONS”. | Divided. The Canadian Cancer Society called on provinces to start screening at 40 on 9 May 2024, before the draft was released, and said afterwards that the draft missed the mark. Several provinces and territories allow self-referral from 40. |
| Colorectal | The Task Force's 2016 guidance covers adults aged 50 and over who are not at high risk, and offers two options, not one: faecal occult blood testing — gFOBT or FIT — every 2 years, or flexible sigmoidoscopy every 10 years. It is a strong recommendation at 60–74 and a weak one at 50–59. It recommends not screening at 75 and over, and — this one catches people — recommends not using colonoscopy as a screening test. | All programmes use FIT. Most screen 50 to 74 every 2 years (Alberta every 1 to 2). Ontario lowered the start age to 45 as of 1 July 2026, and Prince Edward Island moved to 45 in 2026 as well — the first two provinces to do so. Quebec remains 50 to 74. |
Dates matter on this page more than on any other. Check the Task Force and your provincial programme before relying on a number here.
Three practice questions
A 22-year-old woman attends for contraception. She has been sexually active since the age of 16, has had four lifetime partners, and is in a new relationship. She is well, has no abnormal bleeding or discharge, is immunocompetent, and received the HPV vaccine in school. She mentions that a friend in the United States had her first Pap test at 21, and asks whether she should have one now. Which of the following is the most appropriate response?
- A. Perform cervical cytology today, because she has had multiple partners
- B. Explain that cervical screening in Canada generally begins at 25, and offer sexual health care and contraception today
- C. Perform cervical cytology today, because she is in a new relationship
- D. Perform HPV testing today instead of cytology, as this is now the preferred test
- E. Begin annual cervical cytology now and continue annually until the age of 69
Show the answer and explanation
Correct answer: B. Explain that cervical screening in Canada generally begins at 25, and offer sexual health care and contraception today
This is one of the cleanest Canada-versus-United States differences in all of preventive care, and it is tested often. Canadian cervical screening generally begins at 25. The Task Force's published guidance recommends against screening below that age, and the provincial programmes are built the same way.
The reasoning is not that young women do not get HPV — they very commonly do. It is that in this age group the infection usually clears on its own, so screening mostly finds abnormalities that would have resolved. Acting on them means colposcopy and excisional treatment in women who have not yet had children, with a measurable effect on later preterm birth, in exchange for almost no reduction in cervical cancer deaths. The harm is real and the benefit is not.
Notice what none of her history changes. Number of partners, a new relationship, and age at first intercourse do not move the Canadian start age. Her HPV vaccination does not remove the need to screen later, either — she still enters the programme at 25.
Why the other options are wrong
- A. Lifetime partner count is not a criterion for starting cervical screening early in Canada. It feels like a risk factor, which is exactly why it is offered as an option.
- C. A new relationship is a reason to discuss sexually transmitted infection testing and contraception, both of which you should do. It is not a reason for cervical cytology at 22.
- D. HPV primary testing is indeed replacing cytology across Canadian programmes, but that is a change in which test is used, not in when screening starts. At 22 she is below the start age for either test.
- E. Wrong on the start age and wrong on the interval. No Canadian programme screens annually; intervals are measured in years, and lengthen further with HPV-based testing.
A 58-year-old man with no family history of colorectal cancer and no gastrointestinal symptoms completes a fecal immunochemical test through his provincial screening programme. The result is positive. He feels entirely well, his haemoglobin is normal, and he asks whether he can simply repeat the test in a year to see whether it settles. Which of the following is the most appropriate next step?
- A. Repeat the FIT in 12 months, as he is asymptomatic with a normal haemoglobin
- B. Arrange colonoscopy
- C. Arrange CT colonography as the first-line investigation after a positive FIT
- D. Reassure him, since a single positive FIT is commonly a false positive
- E. Start oral iron and repeat the FIT after three months of treatment
Show the answer and explanation
Correct answer: B. Arrange colonoscopy
A positive FIT is not a diagnosis and it is not a result to be repeated. It is the trigger for colonoscopy, which is both the diagnostic test and, for most polyps found, the treatment in the same sitting. Every organised programme in Canada is built on that pathway: FIT to decide who needs a scope, colonoscopy to answer the question.
His being asymptomatic is the entire point of screening, not an argument against acting. Screening exists to find disease in people who feel well; a normal haemoglobin says only that he has not yet bled enough to become anaemic, which is late in the natural history of the thing you are trying to catch early.
For the interval itself: most Canadian programmes offer FIT every 2 years from 50 to 74. Ontario and Prince Edward Island both lowered the start age to 45 during 2026, Ontario with effect from 1 July. Note also what the national guidance says about colonoscopy: the Task Force recommends against using it as a screening test. That does not conflict with this question. Colonoscopy here is the diagnostic test that follows an abnormal screen, which is a different job.
Why the other options are wrong
- A. Repeating a positive screening test to see whether it goes away converts an abnormal result into a year's delay. The programme has already done its job; the next step is diagnostic.
- C. CT colonography has a role where colonoscopy is incomplete, declined or unsafe. It is not the first-line follow-up to a positive FIT, and it cannot remove a polyp.
- D. FIT does produce false positives, which is precisely why a positive result leads to a definitive test rather than to treatment. Reassurance without that test is how a cancer gets missed.
- E. This treats a positive FIT as though it were iron deficiency anaemia, which he does not have. Iron would also obscure the picture without investigating the source.
A 55-year-old woman asks about breast screening. She has no personal history of breast cancer, no known high-risk genetic mutation, no first-degree relative with breast cancer, and no history of chest radiotherapy. She has never had a mammogram. She is well and her examination is normal. Which of the following best reflects the Canadian Task Force's published recommendation for a woman of her age and risk?
- A. Annual mammography
- B. Mammography every 2 to 3 years
- C. Annual mammography combined with screening breast MRI
- D. Clinical breast examination annually, with mammography only if an abnormality is found
- E. No screening is recommended until the age of 65
Show the answer and explanation
Correct answer: B. Mammography every 2 to 3 years
For women aged 50 to 74 who are not at increased risk, the Task Force's 2018 guideline recommends mammography every 2 to 3 years — and so did its 2024 draft, so this answer holds whichever document a question is built on. That interval is longer than the annual screening many candidates expect, and the difference is deliberate: lengthening the interval gives up very little of the mortality benefit while substantially reducing false positives and the biopsies that follow them.
Note what the stem has carefully excluded. No genetic mutation, no first-degree relative, no chest radiotherapy — because any of those would take her out of the average-risk pathway this recommendation covers and into high-risk surveillance, where MRI does have a role.
One honest caveat the exam is unlikely to make you choose between: the position on women aged 40 to 49 is genuinely unsettled in Canada. The 2018 guideline recommends against routine screening in that decade; the 2024 update reframed the decision as a personal choice but was never finalised and now sits archived; the Canadian Cancer Society called for a start age of 40 in May 2024; and several provinces and territories allow self-referral from 40. The Task Force's mandate ended on 31 March 2026 with the question still open. A fair examination question will either avoid that age band or ask you to describe a shared decision rather than pick a side.
Why the other options are wrong
- A. Annual screening is the American pattern and the intuitive answer. The Canadian interval for average-risk women in this age group is 2 to 3 years.
- C. Screening MRI is for women at high risk — a known mutation, a strong family history, or prior chest radiotherapy. The stem rules out all three.
- D. Clinical breast examination is not recommended as a screening test in this guideline, and using it as the gate to mammography inverts the pathway.
- E. Screening is recommended in her age band, not deferred. Waiting to 65 would skip the years in which screening is most clearly beneficial.
Four traps this topic sets
1. American start ages. Cervical screening at 21 and annual mammography are both American patterns. Canada starts cervical screening at 25 and screens the breast every 2 to 3 years from 50.
2. Treating risk factors as start-age modifiers. Partner count, a new relationship, or early first intercourse do not bring cervical screening forward. Genuine high risk — a known mutation, immunosuppression, prior chest radiotherapy — moves a patient to a different pathway entirely, not to an earlier start on the same one.
3. Repeating a positive screening test. Screening tests sort people into "needs a diagnostic test" and "does not". Repeating an abnormal one is always wrong on an exam and usually wrong in life.
4. Assuming one national answer exists. Colorectal screening starts at 45 in Ontario and Prince Edward Island and at 50 in most of the rest of the country. If a stem names a province, that is information.
5. Colonoscopy as a screening test. The Canadian Task Force recommends against using colonoscopy to screen an average-risk population, and no Canadian programme invites people for one. Colonoscopy after an abnormal FIT is a different thing entirely — a diagnostic test, and the right answer. An option offering colonoscopy as the first step for someone with no symptoms and no abnormal screen is wrong on Canadian guidance.
Sources
Every figure on this page is traceable to one of these. Guidelines are revised — open the source before you commit a number to memory.
- Canadian Task Force on Preventive Health Care — published guidelines — the national recommendations, and the status of any update in progress
- Breast cancer screening recommendations, ages 40–74 (CMAJ) — the published guideline, including the 2 to 3 year interval
- Canadian Task Force — breast cancer update, draft recommendations (PDF) — the 2024 draft that reframed ages 40 to 74
- Canadian Task Force — colorectal cancer screening guideline (2016) — FOBT every 2 years or flexible sigmoidoscopy every 10 years, and the recommendation against screening colonoscopy
- Canadian Task Force — cervical cancer screening guideline (2013) — the age bands and the 3-year interval, and the absence of any HPV recommendation
- Canadian Task Force — history, including the end of its mandate — the record that the Task Force ended its mandate on 31 March 2026
- Canadian Partnership Against Cancer — HPV testing in cervical screening — which jurisdictions have implemented HPV testing, and when
- BC Cancer — cervix screening: who should screen — a worked example of a programme interval: 3 years by Pap, 5 years by HPV self-screening
- Canadian Cancer Society — breast screening programmes must start at age 40 (media release, 9 May 2024) — the Society position, and its date
- Canadian Partnership Against Cancer — colorectal screening parameters by province — the start ages and intervals actually in force, jurisdiction by jurisdiction
- Cancer Care Ontario — colorectal cancer screening summary — FIT every 2 years from 45, and the positive-FIT pathway
More free MCCQE1 practice questions
- Prenatal care and screening under the SOGC guidelinesGroup B streptococcus at 35 to 37 weeks, Rh immunoglobulin at 28 weeks, and folic acid dosing that is not what most sources say.
- Acute coronary syndromes and the ECG decisions that followSTEMI recognition, the reperfusion clock, and the patterns that are easy to call wrong.
- Psychiatry: capacity, involuntary admission and the provincial formsWhy certification and incapacity are different findings, and what a Form 1 does and does not authorise.
- Paediatrics: the febrile infant and routine immunisationRisk stratification by age in the first 90 days, and how Canadian schedules are actually organised.
See all free MCCQE1 practice topics →
About these practice pages
MCCQE1 Tutor is a Canadian-guideline preparation platform for the Medical Council of Canada Qualifying Examination Part 1, built by AYRIQ Technologies. The questions on this page were written for this page and are given away free. They are not drawn from the subscriber question bank, so working through them uses up nothing you have paid for.
Practising on Canadian numbers is the whole point. Everything here is free; the platform is where it becomes a study plan.